Support: 888-992-3836
Copyright © 2023 InvestorsHub Inc.
Replies to post #6884 on Theralink Technologies Inc (THER)
CanItBThisEZ2Make
09/20/18 5:18 AM
#6886 RE: learningcurve2020 #6884
Due to the impressive results and proven safety profile of ProscaVax™, OncBioMune is forgoing the 1b portion of the trial to advance ProscaVax™ into Phase 2 studies.